Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Vivaglobin Market Forecast Highlighting Growth From $ Billion To $ Billion
The historical growth can be traced back to several key factors, such as the higher rates at which primary immunodeficiency disorders are now diagnosed, the growing clinical endorsement of subcutaneous immunoglobulin therapies, the broader reach of specialized pharmacy distribution networks, the ongoing availability of plasma-derived treatments, and the increasing recognition among healthcare providers regarding immune-related conditions.
The expansion expected during the forecast period is driven by a surge in the need for self-administered immunoglobulin therapies, the broadening scope of customized immunotherapy strategies, heightened funding allocated to rare disease treatment initiatives, the growing elderly demographic facing immune system challenges, and significant progress in plasma fractionation techniques. Key developments shaping this period include the rising uptake of subcutaneous immunoglobulin delivery methods, a growing inclination toward managing treatments at home, an intensified focus on sustained immune replacement regimens, the proliferation of dosing solutions tailored to individual patient needs, and a strengthened commitment to optimizing therapeutic safety and tolerability.
Download A Free Sample Report For Comprehensive Market Insights:
Vivaglobin Market Opportunity Drivers: What Is Creating New Revenue Potential?
The future expansion of the vivaglobin market is being substantially driven by the growing frequency of primary immunodeficiency diseases (PI). These disorders are characterized by a compromised or missing immune system, which hampers the body’s capacity to fend off infections, resulting in a heightened vulnerability to various illnesses. Several factors contribute to the increasing incidence of Primary Immunodeficiency Diseases, including progress in diagnostic methods, enhanced public and medical awareness of these conditions, improvements in genetic screening, and a more effective identification of cases that were previously undiagnosed. Vivaglobin addresses primary immunodeficiency diseases by delivering a steady supply of antibodies via subcutaneous injection, which boosts the immune system’s capability to fight infections and lowers how often and how severe recurrent illnesses become for affected individuals. As an example, in August 2023, a report published by Thermo Fisher, a life sciences and clinical research firm based in the United States, indicated that approximately 6 million people globally are believed to have a PID. It is also estimated that around 5,000 individuals in the UK suffer from a PID disorder. Consequently, the rising prevalence of Primary Immunodeficiency Diseases is anticipated to spur growth in the vivaglobin market.
A growing commitment to research and development is anticipated to drive future expansion of the vivaglobin market. In the medical field, research and development involve the methodical exploration of novel drugs, treatments, or healthcare technologies with the aim of advancing medical practice. This process encompasses clinical trials, laboratory research, and regulatory checks to verify both safety and effectiveness. Elevated R&D efforts in medicine facilitate the creation of groundbreaking therapies, boost patient outcomes, and tackle newly emerging health issues. Heightened research and development activities aid vivaglobin by fostering innovations in immunoglobulin compositions, refining how the therapy is delivered, and increasing both the effectiveness and accessibility of treatment for individuals with primary immunodeficiency diseases. For example, in April 2025, the Office for National Statistics (ONS), which produces official statistics in the UK, reported that net R&D spending by the UK government grew 8.2% year-on-year, from £16.1 billion in 2022 to £17.4 billion in 2023. Hence, the rising investment in research and development is fueling the vivaglobin market’s expansion.
Growth in the vivaglobin market going forward is set to be propelled by an expanding geriatric population. This demographic segment generally includes older individuals, commonly those aged 65 and above, who frequently encounter distinct health, social, and economic difficulties. The rise in the geriatric population is largely attributable to healthcare improvements that extend life expectancy, combined with reducing birth rates. Vivaglobin benefits the elderly by offering a practical and effective subcutaneous immunoglobulin therapy that fortifies the immune system, thereby decreasing infection risk and enhancing overall quality of life for older adults with weakened immunity or conditions like primary immunodeficiency diseases. To illustrate, in May 2024, the Administration for Community Living, a government agency in the US, reported that in 2022, individuals aged 65 and older made up 17.3% of the population. This share is projected to climb to 22% by 2040. Therefore, the increasing number of geriatric individuals is fostering growth in the vivaglobin market.
Vivaglobin Market Segment Outlook: Which Categories Are Expanding The Fastest?
The vivaglobin market covered in this report is segmented –
1) By Indication: Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Other Indications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies
3) By End User: Adult, Geriatric, Pediatric
Vivaglobin Market Key Companies And Competitive Benchmarking
Major companies operating in the vivaglobin market are CSL Behring GmbH
Access The Complete Vivaglobin Market Report:
Vivaglobin Market Largest Region By Revenue And Market Share
North America was the largest region in the vivaglobin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vivaglobin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model